

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Rolvedon

(eflapegrastim-xnst)

PHYSICIAN INFORMATION			PATIENT INFORMATION					
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax					
Specialty:	* DEA, NP	'l or TIN:	with the outcome of our review unless all asterisked (*) items form are completed.*					
Office Contact Person:			* Patient Name:					
Office Phone:			* Cigna ID: * Date of Birth:			th:		
Office Fax:			* Patient Street Address:					
Office Street Address:			City:	State:		Zip:		
City:	State:	Zip:	Patient Phone:		,			
Urgency: ☐ Standard								
Medication requested: ☐ Rolvedon 13.2mg/0.6mL Solution for Injection ☐ Other (please specify)								
Directions/Duration (fill in blanks and circle appropriate answers):								
Number of cycles planned: mg given every weeks Quantity: Expected duration of therapy: J-Code: ICD10:								
Is this a new start or continuation of therapy? ☐ new start ☐ continuation of therapy Start Date:								
If your patient has already begun treatment with drug samples, please choose "new start of therapy".								
(if continued therapy) Is there documentation of beneficial response with this medication?								
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?								
Where will this medication be obtained?  Accredo Specialty Pharmacy** Hospital Outpatient Hospital - In patient Retail pharmacy Other (please specify):  CPT Code(s):  **Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822)								
NCPDP 4436920), Fax 888								
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code):								
Where will this drug be ☐ Patient's Home ☐ Hospital Outpatient		☐ Physician's Office☐ Other (please specify):						
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.								
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager?								

Clinical Information:	
Is this medication being used in Peripheral Blood Progenitor Cell Collection and Therapy?	☐ Yes ☐ No
(if no) Is the use of this medication related to chemotherapy?	☐ Yes ☐ No
(if no) What is the diagnosis related to use? Please include alternatives tried, date(s) taken and for what the documented results were of taking this drug, including any intolerances or adverse reactic experienced.	
If chemotherapy:	
Does your patient have nonmyeloid cancer (meaning it is NOT related to the bone marrow)?	☐ Yes ☐ No
Please provide the diagnosis related to use and name(s) of the chemotherapy that the patient is currently receiving.	
How many cycles of chemotherapy are planned?	
Will this chemotherapy regimen cause myelosuppression (a decrease in bone marrow activity resulting in fewer red blood cells, and platelets)?	olood cells, white
Which of the following applies to your patient?  patient has a previous history of febrile neutropenia chemotherapy regimen is considered high risk for febrile neutropenia chemotherapy regimen is considered intermediate risk for febrile neutropenia chemotherapy regimen is consider low risk for febrile neutropenia none of the above	
(if intermediate risk) Does your patient have one of the following?  □ prior chemo or radiation □ persistent neutropenia □ bone marrow involvement by tumor □ recent surgery or open wounds □ liver dysfunction □ renal dysfunction □ age 66 years or older AND is receiving full chemo dose intensity □ none of the above	
Is this medication prescribed by or in consultation with an oncologist or hematologist?	☐ Yes ☐ No
Additional Pertinent Information: Please provide clinical support for the use of this drug in your patient (includ stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently).	ing labs, disease
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the insurer its designees may perform a routine audit and request the medical information necessary to verify the accordance information reported on this form.	
Prescriber Signature: Date:	
Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScri	pts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.